Add BrightSurf on Google Email

Science News for December 9, 2007


Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia

Two drugs, dasatinib and nilotinib, are showing promising results as frontline therapy for newly diagnosed CML patients with high complete cytogenetic response rates of approximately 90% at 6 months. The treatments target a greater variety of genetic variations than imatinib, which has increased the 5-year survival rate for CML patient...